Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

238.23 +4.42 (+1.89%)
Streaming Delayed Price Updated: 11:52 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,528
Open 236.29
Bid (Size) 237.74 (4)
Ask (Size) 238.23 (1)
Prev. Close 233.81
Today's Range 234.08 - 239.75
52wk Range 141.97 - 263.73
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Via Benzinga

Performance

YTD
+22.21%
+22.21%
1 Month
-2.09%
-2.09%
3 Month
+65.49%
+65.49%
6 Month
+32.26%
+32.26%
1 Year
+21.92%
+21.92%

More News

Read More
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
$100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Via Benzinga
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
Via InvestorPlace
Exposures Product Safety
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Via InvestorPlace
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Via Benzinga
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Via Investor's Business Daily
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Masters In Trading - Saturday, June 22
Via Talk Markets
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.